Abstract： Objective： To analyze the mechanism of Huanglian Jiedu Decoction in treating Alzheimer's disease （AD） and Epilepsy （EP） using network pharmacology and molecular docking technology. Methods： Active ingredients and corresponding targets of Huanglian Jiedu Decoction were predicted from TCMSP，BATMAN，ETCM， HERB， SYMMAP， and TCMID； disease targets for AD and EP were retrieved from GeneCards， CTD， and OpenTargets； overlapping targets were screened via STRING and Cytoscape and received visual analysis. GO and KEGG enrichment analyses were performed using R Language to construct "active ingredient-overlapping target- pathway" network；molecular docking was verified using AutoDock Tools. Results：A total of 132 active ingredients， 1 439 drug targets， 229 disease targets related to AD and EP， and 152 overlapping targets were identified. Network pharmacology screening revealed five primary active ingredients： quercetin， berberine， wogonin， baicalein， and baicalin. Core targets were TP53， JUN， AKT1， IL-6， and TNF， etc. GO function enrichment analysis revealed 2 231 BP，85 CC and 147 MF terms；KEGG identified 192 pathways，including TNF，lipids and advanced glycation end products and their receptors （AGE-RAGE） in atherosclerosis and diabetic complications；the results of molecular docking showed that the binding energy of the main active ingredients and the core target molecules was lower than -5.0 kcal/mol，indicating strong binding affinity. Conclusion：Through quercetin，berberine，wogonin，baicalein， and baicalin，Huanglian Jiedu Decoction can act on targets such as TP53，JUN，AKT1，IL-6，and TNF，regulate the pathways of AGE-RAGE，TNF，and lipid and atherosclerosis in diabetic complications，so as to play the role of treating AD and EP with the same therapy.